

# How should we treat major depression combined with anxiety?

\*BONNIE TROTTER, MD, MPH; GARY KELSBERG, MD;

\*\*LEILANI ST. ANNA, MLIS, AHIP

\*Valley Family Medicine Residency, Renton, Wash

\*\*University of Washington Health Sciences Libraries, Seattle

## EVIDENCE-BASED ANSWER

One approach is to use antidepressants alone, which reduce symptoms for patients with major depression plus symptoms of anxiety or major depression plus generalized anxiety disorder. Selective serotonin reuptake inhibitors (SSRIs), tricyclics (TCAs), bupropion, mirtazapine, nefazodone, and venlafaxine are equally effective for combined symptom relief (strength of recommendation [SOR]: **A**, based on systematic review of randomized controlled trials [RCTs]).

Another approach is to add a benzodiazepine to the antidepressant. This reduces anxiety symptoms (more in the short term) and decreases patient dropout, but it also has possible harms, including development of dependence and accident proneness (SOR: **A**, based on systematic review of RCTs).

Psychotherapy, particularly cognitive behavioral therapy, produces and maintains reductions in symptoms of anxiety and depression that are comparable with the reductions seen with medication (SOR: **A**, based on systematic review of RCTs). □

## EVIDENCE SUMMARY

### Antidepressants have similar positive effects

A systematic review of 28 randomized trials comparing various antidepressant medications found no significant differences in reduction of symptoms of depression and anxiety for patients who had both. (2) Patients in these trials met *DSM* (*Diagnostic and Statistical Manual of Mental Health*) criteria for major depression, with symptom severity as measured by a standardized scale, the Hamilton Rating Scale for Depression (HAM-D). They also had moderate to severe levels of anxiety symptoms as measured by standardized scales (Hamilton Rating Scale for Anxiety [HAM-A], Covi Anxiety Rating Scale, or the anxiety/somatization factors on the HAM-D).

## CLINICAL COMMENTARY

**Talk to the patient about risks and benefits of drug therapy, and the need to closely monitor him in the first few weeks**

**Vincent Lo, MD**

*San Joaquin Family Medicine Residency, French Camp, Calif*

*Such discussions are essential, in light of the Food and Drug Administration's mandate that all classes of antidepressant carry a black box warning label about increased suicidality (suicidal thinking and behavior) among patients taking these medications. (1)*

*Benzodiazepine medications are effective in mitigating symptoms of anxiety but have additional risks such as altered cognition, tolerance, and abuse potential. In addition, benzodiazepine can be lethal in overdose with alcohol. Therefore, using a benzodiazepine alone for a patient who has both anxiety and depression is unwise. Even when used in combination with an antidepressant, benzodiazepine therapy should be brief. □*

## FAST TRACK

*Explain why close monitoring is a necessity for the first few weeks.*

Trials ranged from 6 to 24 weeks long, with outcomes including reductions in depression and anxiety symptom scores as measured by standardized scales. Study quality was variable; only 8 trials used a placebo control, and many were sponsored by pharmaceutical manufacturers.

Although some individual studies found differences in outcomes between medications, no significant differences in efficacy were seen in combined data from each comparison group. Medication was more efficacious than placebo in most studies that used a placebo control. Side-effect profiles were not described.

Patients with major depression and high anxiety levels relapsed more often than those with low anxiety levels with discontinuation of fluoxetine compared with placebo in a double-blind placebo-controlled parallel trial with 596 patients. (3)

Three trials evaluated antidepressant medication for patients who met diagnostic criteria for both major depression and generalized anxiety disorder. A manufacturer-sponsored RCT (N=90) found no differences in HAM-A or HAM-D score reduction among fluoxetine, venlafaxine, and placebo (except at 12 weeks, when venlafaxine significantly differed from placebo). (4) Two open-label cohort trials (N=153) found that fluoxetine and fluvoxamine (Luvox, an older SSRI) reduced both depression and anxiety by about half. (5,6) □

### ADDING BENZODIAZEPINES IS NOT A LONG-TERM SOLUTION

A Cochrane systematic review (10 RCTs, N=731) compared antidepressants alone vs combinations with benzodiazepines for patients with major depression and a 35% to 85% estimated prevalence of anxiety symptoms. Three studies used standardized scales to measure anxiety symptom severity.

Antidepressants in combination with benzodiazepines were more likely than antidepressants alone to reduce depression scores by 50% or more (for 50% depression improvement at 1 week, number needed to treat [NNT]=12; at 4 weeks, NNT=8). The combination group also had fewer dropouts (relative risk [RR]=0.63, 95% confidence interval [CI], 0.49-0.81). The authors concluded that potential benefits of adding a benzodiazepine to an antidepressant must be balanced against possible harms, such as the development of dependence. (7) □

### PSYCHOTHERAPY APPEARS LIKELY TO HELP

A review of 13 controlled clinical trials (8) evaluated standardized depression and anxiety score reductions for patients with generalized anxiety disorder receiving cognitive behavioral therapy compared with various control treatments (waiting list, pill placebo, or alternative therapy-such as supportive listening psychotherapy). Approxi-

mately half of the patients were also taking medication (not specified).

After an average of 10 sessions, cognitive behavioral therapy reduced anxiety and depression symptom scores more than control treatments (difference in effect size were 0.71 and 0.66, respectively). At 6- to 12-month follow-up, cognitive behavioral therapy gains were maintained (difference in effect size = 0.30 for anxiety scores and 0.21 for depression scores). (An effect size of 0.2 is usually considered small, 0.5 moderate, and 0.8 is large.)

#### FAST TRACK

*Relapse was more likely with high anxiety levels than with low anxiety levels, when fluoxetine was discontinued.*

Another trial assigned primary care patients (N = 464) with depression or mixed depression and anxiety to 1 of 2 psychological therapy groups (cognitive behavioral therapy or non-directive counseling for 12 sessions) vs usual general practitioner care. At 4 months, both psychological therapy groups had lower Beck Depression Index scores (by 4-5 points) than the usual general practitioner care group, but by 12 months there were no significant differences among all groups. (9) □

### RECOMMENDATIONS FROM OTHERS

The National Collaborating Centre for Mental Health guidelines state: “when depressive symptoms are accompanied by anxious symptoms, the first priority should usually be to treat the depression. Psychological treatment for depression often reduces anxiety, and many antidepressants also have sedative/anxiolytic effects.” (10)

#### FAST TRACK

*10 psychotherapy sessions led to lower depression and anxiety scores, which were maintained after a year.*

The Brigham and Women’s Hospital guideline recommends adjunctive therapy with anxiolytics – such as lorazepam (Ativan) and clonazepam (Klonopin) – for some patients with depression and mild to moderate anxiety, to help control symptoms such as sleeplessness and restlessness. (11) □

## REFERENCES

1. US Food and Drug Administration web site – Antidepressant use in children, adolescents and adults. Available at: [www.fda.gov/cder/drug/antidepressants/default.htm](http://www.fda.gov/cder/drug/antidepressants/default.htm). Accessed on March 7, 2007.
2. Panzer MJ – Are SSRIs really more effective for anxious depression? *Ann Clin Psychiatry* 2005;17:23–29.
3. Joliat MJ, Schmidt ME, Fava M, Zhang S, Michelson D, Trapp NJ, Miner CM – Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. *J Clin Psychiatry* 2004;65:373–378.
4. Silverstone PH, Salina E – Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. *J Clin Psychiatry* 2001;62:523–529.
5. Sonawalla SB, Farabaugh A, Johnson MW, et al – Fluoxetine treatment of depressed patients with comorbid anxiety disorder. *J Psychopharmacol* 2002;16:215–219.
6. Sonawalla SB, Spillman MK, Kolsky AR, et al – Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. *J Clin Psychiatry* 1999;60:580–583.
7. Furukawa TA, Streiner DL, Young LT, Kinoshita Y – Antidepressants plus benzodiazepines for major depression. *Cochrane Database Syst Rev* 2001;(2):CD001026.
8. Borkovec TD, Ruscio AM – Psychotherapy for generalized anxiety disorder. *J Clin Psychiatry* 2001;62(suppl 11):37–42.
9. King M, Sibbald B, Ward E, et al – Randomised controlled trial of non-directive counseling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. *Health Technol Assess* 2000;4(19):1–83.
10. National Collaborating Centre for Mental Health – *Depression: Management of Depression in Primary and Secondary Care*. London, England: National Institute for Clinical Excellence (NICE); 2004. Available at: [www.nice.org.uk/page.aspx?o=cg023](http://www.nice.org.uk/page.aspx?o=cg023). Accessed on March 21, 2007.
11. Brigham and Women's Hospital – *Depression: A Guide to Diagnosis and Treatment*. Boston, Mass: Brigham and Women's Hospital; 2001. Available at: [www.brighamandwomens.org/medical/handbookarticles/depression/depression\\_frame.asp](http://www.brighamandwomens.org/medical/handbookarticles/depression/depression_frame.asp). Accessed on March 21, 2007.

©2007, Dowden Health Media, Inc. All rights reserved. This article was reprinted from the original article published in *The Journal of Family Practice*, April 2007, Vol. 56, No. 4, pp 306-308, a publication of Dowden Health Media, Inc.

### Revista presei medicale românești și internaționale

#### Burger King to limit ads aimed at children under 12

NICHOLA GROOM

LOS ANGELES (Reuters) – Fast-food chain Burger King Holdings Inc said on Tuesday that, beginning late next year, it will limit advertising aimed at children younger than 12 to food and drinks that meet strict nutritional guidelines.

In conjunction with the Council for Better Business Bureaus' children's food and beverage advertising initiative, Burger King has agreed that, by December 2008, it will limit advertising aimed at children under 12 years old to Kids Meals that provide no more than 560 calories per meal, have less than 30 percent calories from fat and no added trans fats.

Other U.S. food and beverage companies who have joined the

initiative include Burger King rival McDonald's Corp, Campbell Soup Co, General Mills Inc, PepsiCo Inc, Kraft Foods Inc, Coca-Cola Co, Hershey Co, Kellogg Co, Mars Inc, Unilever United States and Cadbury Adams USA.

As part of its new commitment, Burger King is currently developing a new, healthier meal for children that will include flame broiled chicken tenders in the shape of a Burger King crown, organic unsweetened apple sauce, low-fat milk and fresh apple slices called Apple Fries.

The chicken tenders will replace fried tenders and the unsweetened apple sauce will replace a sweetened

version currently available in the company's Kids Meals, said spokesman Keva Silversmith.

The new meal will be available nationwide in the spring or summer of next year, Silversmith added, saying it takes time to roll out new products to more than 7,000 restaurants.

"It's really a supply issue and a logistical issue of rolling out the new products to a system this size," he said.

Advertising for the new products will not begin until late next year, once they are established in the restaurants, Silversmith said. In the meantime, Burger King will limit its advertising to kids younger than 12 to its healthiest options, he added.

Reuters Health